Peroxisome proliferator-activated receptor α,γ coagonist LY465608 inhibits macrophage activation and atherosclerosis in apolipoprotein E knockout mice

Lipids

Volumn 37, Issue 5, 2002, Pages 487-494

  Zuckerman, Steven H ^a   Kauffman, Raymond F ^a   Evans, Glenn F ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; DISEASES; INTERFERONS; NITROGEN OXIDES; SYNTHESIS (CHEMICAL);

CELLULAR PROCESSES;

LIPIDS;

APOLIPOPROTEIN E; BETA2 INTEGRIN; LY 465608; NITRIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; CELL RECEPTOR; ORGANIC COMPOUND; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CELL FUNCTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; KNOCKOUT MOUSE; MACROPHAGE ACTIVATION; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; ANIMAL; AORTA; ARTERIOSCLEROSIS; DRUG POTENTIATION; GENE DELETION; GENETICS; IN VITRO STUDY; METABOLISM; MOUSE MUTANT; PATHOLOGY;

ANIMALIA;

ANIMALS; AORTA; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; GENE DELETION; HYPOGLYCEMIC AGENTS; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, KNOCKOUT; ORGANIC CHEMICALS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 0035999532     PISSN: 00244201     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11745-002-0922-2     Document Type: Article

References (50)

1. Atherosclerosis - An inflammatory disease
2. Atherosclerosis: Basic mechanisms, oxidation, inflammation, and genetics
3. Macrophages and atherosclerotic plaque stability
4. Expression of macrophage scavenger receptor in atherosclerosis: Relationship between scavenger receptor isoforms and the T cell cytokine, interferon-γ
5. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries
6. Cell-mediated immunity in atherosclerosis
7. Interferon-gamma inhibits macrophage apolipoprotein E production by posttranslational mechanisms
8. Cytokine regulation of macrophage Apo E secretion: Opposing effects of GM-CSF and TGF-β
9. Interferon-gamma induces downregulation of tangier disease gene (ATP-binding-cassette transporter 1) in macrophage-derived foam cells
10. Regulation of cholesterol distribution in macrophage -derived foam cells by gamma interferon (IFN-γ)
11. Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E-/- mice
12. Cellular responses to interferon-γ
13. IFN-γ potentiates atherosclerosis in ApoE knockout mice
14. The nuclear receptor superfamily: The second decade
15. The molecular and genetic dissection of the retinoid signaling pathway
16. Interaction of the peroxisome-proliferator-activated receptor and retinoid X Receptor
17. The peroxisome proliferator-activated receptor γ (PPARγ) as a regulator of monocyte/macrophage function
18. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor γ (PPARγ) agonists
19. Activation of PPARα or γ reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1
20. Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1
21. Induction of IκBα Expression as a Mechanism Contributing to the Anti-inflammatory Activities of Peroxisome Proliferator-Activated Receptor-α Activators
22. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
23. Inhibition of inducible nitric oxide synthase by peroxisome proliferator-activated receptor agonists: Correlation with induction of heme oxygenase 1
24. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
25. Macrophages in human atheroma contain PParγ. Differentiation-dependent peroxisomal proliferator-activated receptor γ (PPARγ) expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes in vitro
26. A PPARγ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis
27. CLA-I/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors
28. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL
29. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ
30. 2
31. PPAR activators inhibit thrombin induced endothelin-1 production in human vascular endothelial cells by inhibiting the AP-1 signaling pathway
32. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor
33. Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice
34. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice
35. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice. Pleiotropic effects on CD36 expression and HDL
36. The design and synthesis of 2-methyl-2-{4-[2-(5-methyl-2-aryloxazol-4-yl)ethoxy]phenoxy} propionic acids: A new class of PPARα,γ agonists
37. Estrogen-mediated increases in LDL cholesterol and foam cell-containing lesions in human ApoB100 x CETP transgenic mice
38. Inhibition of cholesteryl ester transfer protein in normocholesterolemic and hypercholesterolemic hamsters: Effects on HDL subspecies, quantity, and apoprotein distribution
39. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers
40. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and γ
41. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ
42. Role of the peroxisome proliferator-activated receptor in mediating the effects of fibrates and fatty acids on gene expression
43. The emergence of mouse models of atherosclerosis and their relevance to clinical research
44. Atherosclerosis: From lesion formation to plaque activation and endothelial dysfunction
45. Role of the peroxisome proliferator-activated receptor (PPAR) in atherosclerosis
46. Peroxisome proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity
47. Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight
48. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not PPARγ activators
49. Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages
50. Role for peroxisome proliferator-activated receptor α in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells